|
ENGOT-EN6/NSGO-RUBY: A phase III, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC). |
|
|
Leadership - Karyopharm Therapeutics; SeraCare |
Stock and Other Ownership Interests - Karyopharm Therapeutics; SeraCare |
Honoraria - Advaxis; AstraZeneca; Cerulean Pharma; Clovis Oncology; Novocure; Pfizer; Roche; tesaro |
Consulting or Advisory Role - AstraZeneca; BioCad; Cerulean Pharma; Clovis Oncology; Genmab; Karyopharm Therapeutics; Novocure; Pfizer; Sotio; Tesaro |
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Pfizer (Inst); Tesaro (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Karyopharm Therapeutics; Pfizer; Roche; SeraCare; Tesaro |
|
|
Consulting or Advisory Role - Abbvie; Abbvie/Stemcentrx; Agenus; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Genentech/Roche; Genmab; Immunogen; Novocure; Oncolytics; OncoMed; OncoSec; Sotio; Tesaro |
Research Funding - Abbott/AbbVie; Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Johnson & Johnson; Merck; OncoMed; Roche/Genentech |
Travel, Accommodations, Expenses - Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Clovis Oncology; GOG Foundation; Merck; Research to Practice; Roche/Genentech; Sotio; Vaniam Group |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Clovis Oncology; Roche Pharma AG; Tesaro |
Travel, Accommodations, Expenses - AstraZeneca; Intuitive Surgical; PharmaMar; Roche Pharma AG; Tesaro |
|
|
Consulting or Advisory Role - GlaxoSmithKline |
|
|
No Relationships to Disclose |
|
|
Employment - GlaxoSmithKline |
Stock and Other Ownership Interests - GlaxoSmithKline |
|
|
Employment - GlaxoSmithKline |
Stock and Other Ownership Interests - Tesaro |
Travel, Accommodations, Expenses - Tesaro |
|
|
Employment - GlaxoSmithKline |
Stock and Other Ownership Interests - GlaxoSmithKline |
|
|
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Roche/Genentech; Tesaro |
Speakers' Bureau - AstraZeneca; Clovis Oncology; Genentech/Roche; Tesaro |